Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Retained Earnings (2016 - 2025)

Spyre Therapeutics' Retained Earnings history spans 11 years, with the latest figure at $869000.0 for Q4 2025.

  • For Q4 2025, Retained Earnings rose 100.09% year-over-year to $869000.0; the TTM value through Dec 2025 reached $869000.0, up 100.09%, while the annual FY2025 figure was $869000.0, 100.09% up from the prior year.
  • Retained Earnings reached $869000.0 in Q4 2025 per SYRE's latest filing, up from -$1.1 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $1.5 million in Q3 2024 to a low of -$1.1 billion in Q3 2025.
  • Average Retained Earnings over 5 years is -$352.7 million, with a median of -$150.8 million recorded in 2021.
  • Peak YoY movement for Retained Earnings: skyrocketed 118.66% in 2021, then crashed 13471566.67% in 2024.
  • A 5-year view of Retained Earnings shows it stood at -$20000.0 in 2021, then crashed by 2128020.0% to -$425.6 million in 2022, then surged by 100.07% to $302000.0 in 2023, then tumbled by 322097.35% to -$972.4 million in 2024, then surged by 100.09% to $869000.0 in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Retained Earnings are $869000.0 (Q4 2025), -$1.1 billion (Q3 2025), and -$1.1 billion (Q2 2025).